Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Index
-
Market Cap
1.74B
Enterprise Value
1.94B
Income
-
Sales
-
Book/sh
-4.25
Cash/sh
3.50
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
72
IPO
May 01, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
10.62
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
12.85
Current Ratio
12.85
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-2.47
EPS next Q
-0.74
EPS this Y
95.85%
EPS next Y
11.87%
EPS next 5Y
64.31%
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Insider Own
28.79%
Insider Trans
28.36%
Inst Own
32.90%
Inst Trans
0.36%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
23.38%
SMA50
31.72%
SMA200
31.72%
Trades
Shs Outstand
46.71M
Shs Float
33.26M
52W High
38.87 -4.28%
52W Low
23.00 61.74%
Volatility
11.34% 11.62%
ATR (14)
3.40
RSI (14)
63.03
Beta
-
Rel Volume
0.88
Avg Volume
354.15K
Volume
313,303
Perf Week
14.46%
Perf Month
45.60%
Perf Quarter
-
Perf Half Y
-
Perf YTD
37.78%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
33.89
Price
37.20
Change
9.77%
Date Action Analyst Rating Change Price Target Change
Jun-17-26Initiated H.C. Wainwright Buy $40
May-26-26Initiated Wedbush Outperform $42
May-26-26Initiated Jefferies Buy $39
May-26-26Initiated Goldman Buy $36
May-26-26Initiated Evercore ISI Outperform $50
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded on February 12, 2026 and is headquartered in Cambridge, MA.
Ph.D.Dr. Benny Sorensen M.D.
CFO & GMMr. Mads Nikolaj Behrndt-Eriksen M.Sc.
Chief Medical OfficerDr. Catherine Eilleen Madigan M.D.
Ph.D.Dr. Ananthram Sreenivasa Murthy M.Sc.
Senior Vice President of CMC & ManufacturingMs. Cecile Bonvoisin M.Sc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.10% OwnerJun 16 '26Buy24.9861,5231,536,8456,444,637Jun 17 06:24 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJun 15 '26Buy24.896,146152,9746,383,114Jun 17 06:24 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 19 '26Buy24.973,80294,9366,375,972May 21 04:20 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 20 '26Buy24.9499624,8406,376,968May 21 04:20 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 12 '26Buy24.906,387159,0366,372,170May 14 05:21 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 11 '26Buy24.8139,869989,2266,365,783May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 07 '26Buy24.469,906242,3236,324,431May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 08 '26Buy24.981,48337,0456,325,914May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 04 '26Buy18.002,675,00048,150,0006,149,096May 06 07:16 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 05 '26Buy24.6397,4112,399,5466,246,507May 06 07:16 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 06 '26Buy24.6068,0181,673,3996,314,525May 06 07:16 PM